Breaking Finance News

Foundation Medicine Inc (NASDAQ:FMI) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $23.57, Foundation Medicine Inc (NASDAQ:FMI) traded 0.47% higher on the day. With the last stock price up 16.36% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. FMI has recorded a 50-day average of $22.62 and a two hundred day average of $20.26. Trade Volume was down over the average, with 156,984 shares of FMI changing hands under the typical 190,880

Zacks Investment Research has upgraded Foundation Medicine Inc (NASDAQ:FMI) to Hold in a statement released on Tuesday October 04, 2016.

On Wednesday September 21, 2016, UBS Securities released a statement about Foundation Medicine Inc (NASDAQ:FMI) upped the target price from $16.00 to $22.00 that suggested a downside of -0.04%.

Recent Performance Chart

Foundation Medicine Inc (NASDAQ:FMI)

Foundation Medicine Inc has with a one year low of $13.34 and a one year high of $25.31 and has a market capitalization of $0.

General Company Details For Foundation Medicine Inc (NASDAQ:FMI)

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company's segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *